Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for SRx Health Solutions (SRXH) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • SRx Health Solutions' Cash & Equivalents rose 113490.57% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 113490.57%. This contributed to the annual value of $1.3 million for FY2025, which is N/A changed from last year.
  • As of Q3 2025, SRx Health Solutions' Cash & Equivalents stood at $1.3 million, which was up 113490.57% from $912000.0 recorded in Q2 2025.
  • SRx Health Solutions' Cash & Equivalents' 5-year high stood at $28.9 million during Q4 2021, with a 5-year trough of $106000.0 in Q3 2024.
  • Its 5-year average for Cash & Equivalents is $7.3 million, with a median of $3.8 million in 2023.
  • As far as peak fluctuations go, SRx Health Solutions' Cash & Equivalents skyrocketed by 452664.3% in 2021, and later plummeted by 9721.05% in 2024.
  • SRx Health Solutions' Cash & Equivalents (Quarter) stood at $28.9 million in 2021, then crashed by 67.27% to $9.5 million in 2022, then tumbled by 52.97% to $4.5 million in 2023, then tumbled by 31.18% to $3.1 million in 2024, then plummeted by 57.31% to $1.3 million in 2025.
  • Its Cash & Equivalents was $1.3 million in Q3 2025, compared to $912000.0 in Q2 2025 and $1.1 million in Q1 2025.